GoAI
Get started
Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.07

+$0.05 · +2.48%

Aug 21, 4:00 PM ET

IPSC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

68

Undervalued

Momentum

60

Neutral

Sentiment

33

Bearish

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Brent Pfeiffenberger
Listed since
Jun 18, 2021
Employees
78

Market position

Day range

Current $2.07

52-week range

Current $2.07

Open
$2.05
Previous close
$2.02
Volume
330.59K
0.3× average
Average volume
1.09M
Average daily volume
Market cap
179.2M USD
Beta
1.6
Market reference 1
50-day average
$2.1712
-4.66% below average
200-day average
$1.8695
+10.73% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
67.82M USD
P/E (TTM)
-1.99×
P/B (TTM)
1.83×
P/S (TTM)
0×
EV / EBITDA
19.64×
Earnings yield
-11.13%
Free cash flow yield
-121.62%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-6.03%
Return on assets
-4.28%
Return on invested capital
-7.22%

Financial health

Debt / equity
0.15×
Current ratio
5.97×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends766%-1897%-4560%-7223%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 88.00%Operating margin, FY2022: -2574.17%Operating margin, FY2023: -6556.87%Operating margin, FY2024: -2096.48%Operating margin, FY2025: -13.78%Net margin, FY2022: -2518.41%Net margin, FY2023: -6115.12%Net margin, FY2024: -1920.87%Net margin, FY2025: -8.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 88.00%. Operating margin FY2022 -2574.17%. Operating margin FY2023 -6556.87%. Operating margin FY2024 -2096.48%. Operating margin FY2025 -13.78%. Net margin FY2022 -2518.41%. Net margin FY2023 -6115.12%. Net margin FY2024 -1920.87%. Net margin FY2025 -8.78%.

Income trends

Revenue

109.16M USD+1556.76%

Operating income

−15.04M USD+89.11%

Net income

−9.58M USD+92.43%
Income trends across reported periods134.74M USD32.45M USD−69.83M USD−172.12M USDRevenue, FY2022: 5.2M USDRevenue, FY2023: 2.24M USDRevenue, FY2024: 6.59M USDRevenue, FY2025: 109.16M USDOperating income, FY2021: −94.88M USDOperating income, FY2022: −133.83M USDOperating income, FY2023: −146.55M USDOperating income, FY2024: −138.14M USDOperating income, FY2025: −15.04M USDNet income, FY2021: −95.82M USDNet income, FY2022: −130.93M USDNet income, FY2023: −136.67M USDNet income, FY2024: −126.57M USDNet income, FY2025: −9.58M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 5.2M USD. Revenue FY2023 2.24M USD. Revenue FY2024 6.59M USD. Revenue FY2025 109.16M USD. Operating income FY2021 −94.88M USD. Operating income FY2022 −133.83M USD. Operating income FY2023 −146.55M USD. Operating income FY2024 −138.14M USD. Operating income FY2025 −15.04M USD. Net income FY2021 −95.82M USD. Net income FY2022 −130.93M USD. Net income FY2023 −136.67M USD. Net income FY2024 −126.57M USD. Net income FY2025 −9.58M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue109.16M USD6.59M USD2.24M USD5.2M USD—
Cost of goods sold13.1M USD———4.58M USD
Gross profit96.06M USD6.59M USD2.24M USD5.2M USD−4.58M USD
Research and development95.67M USD107.24M USD92.71M USD97.17M USD75.65M USD
Selling, general, and administrative24M USD33.16M USD34.71M USD31.86M USD14.65M USD
Operating expenses111.1M USD144.73M USD148.78M USD139.03M USD90.3M USD
Interest income7.35M USD13.01M USD12.68M USD2.99M USD898K USD
Interest expense——540K USD—1.28M USD
Depreciation and amortization13.1M USD13.3M USD13.04M USD8.44M USD4.58M USD
Operating income−15.04M USD−138.14M USD−146.55M USD−133.83M USD−94.88M USD
Net income−9.58M USD−126.57M USD−136.67M USD−130.93M USD−95.82M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 2 misses, 1 met estimate
Average EPS surprise
+38.91%
11 comparable reports
Latest EPS result
-0.17
Estimate -0.11 · Miss by 54.55%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates10.48-0.04-0.56Q1 '25BeatQ2 '25BeatQ3 '25MetQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -0.43, estimate -0.45, surprise +4.44%, Beat. Q2 2025, reported May 15, 2025: actual 0.89, estimate -0.31, surprise +387.10%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.38, estimate -0.38, surprise 0.00%, Met estimate. Q4 2025, reported Nov 13, 2025: actual -0.32, estimate -0.39, surprise +17.95%, Beat. Q1 2026, reported Mar 12, 2026: actual -0.25, estimate -0.28, surprise +10.71%, Beat. Q2 2026, reported May 13, 2026: actual -0.11, estimate -0.15, surprise +26.67%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.17, estimate -0.11, surprise -54.55%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates117.9M75.66M33.42M-8.82MQ1 '25MissQ2 '25BeatQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual 4.17M USD, estimate 49.55M USD, surprise -91.58%, Miss. Q2 2025, reported May 15, 2025: actual 109.16M USD, estimate 41.29M USD, surprise +164.37%, Beat. Q3 2025, reported Aug 14, 2025: actual —, estimate 25K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual —, estimate -83.33K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 12, 2026: actual —, estimate -62.5K USD, surprise —, Comparison unavailable. Q2 2026, reported May 13, 2026: actual —, estimate 2.87M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 12, 2026: actual —, estimate 2.17M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.63M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.00

3.38% downside
Past 12 months12-month forecastHigh $2.00Average $2.00Low $2.00

Rating distribution

9 ratings
Strong buy00%
Buy778%
Hold222%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions
Leerink PartnersdowngradeOutperformMarket Perform
Canaccord GenuitymaintainBuy
JP MorgandowngradeOverweightNeutral

IPSC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IPSC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.77M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.01M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.47M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.22M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.39M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
859.32K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco Russell 2000 Dynamic Multifactor ETF logoInvesco Russell 2000 Dynamic Multifactor ETFOMFS
Market value
448.67K
Weight
0.16%
AUM
285.96M USD
Expense ratio
0.39%
Price / 1D
$53.21+0.87%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
406.3K
Weight
0.01%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research IPSC

research.disclaimer